Ewe K, Eckardt V, Kanzler G
I Medizinische Klinik und Poliklinik der Johannes Gutenberg-Universität, Mainz, West Germany.
Scand J Gastroenterol Suppl. 1988;148:70-5. doi: 10.3109/00365528809101553.
The effects of olsalazine were studied mainly in patients with ulcerative colitis who were intolerant to sulphasalazine, and for relapse prevention. A crossover design with sulphasalazine, 3 g/day, and olsalazine, 1.5 g/day, was applied to compare the side-effects of each drug and to evaluate their therapeutic efficacy. A total of 41 patients with mild or moderately severe left-sided colitis or proctitis were assigned to a randomized treatment schedule. Olsalazine and sulphasalazine were similar in their therapeutic efficacy. Twelve patients complained of adverse effects while on sulphasalazine and 4 patients during olsalazine treatment (p less than 0.05). It is concluded that olsalazine is a safe and effective drug for the treatment of mild or moderately severe ulcerative colitis, and is comparable to sulphasalazine, though with reduced side-effects.
奥沙拉嗪的疗效主要在对柳氮磺胺吡啶不耐受的溃疡性结肠炎患者中进行研究，用于预防复发。采用交叉设计，分别给予柳氮磺胺吡啶每日3克和奥沙拉嗪每日1.5克，比较每种药物的副作用并评估其治疗效果。总共41例轻度或中度重度左侧结肠炎或直肠炎患者被分配到随机治疗方案中。奥沙拉嗪和柳氮磺胺吡啶的治疗效果相似。12例患者在服用柳氮磺胺吡啶时出现不良反应，4例患者在服用奥沙拉嗪时出现不良反应（p<0.05）。结论是，奥沙拉嗪是治疗轻度或中度重度溃疡性结肠炎的一种安全有效的药物，与柳氮磺胺吡啶相当，但副作用较少。
